On Jan 17, Simcere Pharmaceutical Group announced that the NDA of XIANNUOXIN, a #COVID19 antiviral drug jointly developed by Simcere, Shanghai Institute of Materia Medica, Wuhan Institute of Virology and the Chinese Academy of Sciences, has been accepted by NMPA.
XIANNUOXIN could become the 2nd...